Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 679

1.

Evaluation of a new robotic-assisted laparoscopic surgical system for procedures in small cavities.

Bergholz R, Botden S, Verweij J, Tytgat S, Van Gemert W, Boettcher M, Ehlert H, Reinshagen K, Gidaro S.

J Robot Surg. 2019 Apr 16. doi: 10.1007/s11701-019-00961-y. [Epub ahead of print]

PMID:
30993523
2.

Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A.

Wajja A, Namutebi M, Apule B, Oduru G, Kiwanuka S, Akello M, Nassanga B, Kabagenyi J, Mpiima J, Vermaak S, Lawrie A, Satti I, Verweij J, Cose S, Levin J, Kaleebu P, Tukahebwa E, McShane H, Elliott AM.

Wellcome Open Res. 2018 Sep 19;3:121. doi: 10.12688/wellcomeopenres.14736.1. eCollection 2018.

3.

Innovation in oncology clinical trial design.

Verweij J, Hendriks HR, Zwierzina H; Cancer Drug Development Forum.

Cancer Treat Rev. 2019 Mar;74:15-20. doi: 10.1016/j.ctrv.2019.01.001. Epub 2019 Jan 4. Review.

PMID:
30665053
4.

Surrogate endpoints in advanced sarcoma trials: a meta-analysis.

Savina M, Litière S, Italiano A, Burzykowski T, Bonnetain F, Gourgou S, Rondeau V, Blay JY, Cousin S, Duffaud F, Gelderblom H, Gronchi A, Judson I, Le Cesne A, Lorigan P, Maurel J, van der Graaf W, Verweij J, Mathoulin-Pélissier S, Bellera C.

Oncotarget. 2018 Oct 2;9(77):34617-34627. doi: 10.18632/oncotarget.26166. eCollection 2018 Oct 2.

5.

The impact of intensive versus standard anthelminthic treatment on allergy-related outcomes, helminth infection intensity and helminth-related morbidity in Lake Victoria fishing communities, Uganda: results from the LaVIISWA cluster randomised trial.

Sanya RE, Nkurunungi G, Hoek Spaans R, Nampijja M, O'Hara G, Kizindo R, Oduru G, Kabuubi Nakawungu P, Niwagaba E, Abayo E, Kabagenyi J, Zziwa C, Nakazibwe E, Tumusiime J, Kaweesa J, Muwonge Kakooza F, Akello M, Lubyayi L, Verweij J, Nash S, van Ree R, Mpairwe H, Tukahebwa E, Webb EL, Elliott AM; LaVIISWA trial team.

Clin Infect Dis. 2018 Sep 8. doi: 10.1093/cid/ciy761. [Epub ahead of print]

6.

Melanopsin expression in the cornea.

Delwig A, Chaney SY, Bertke AS, Verweij J, Quirce S, Larsen DD, Yang C, Buhr E, VAN Gelder R, Gallar J, Margolis T, Copenhagen DR.

Vis Neurosci. 2018 Jan;35:E004. doi: 10.1017/S0952523817000359.

7.

Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial.

Issels RD, Lindner LH, Verweij J, Wessalowski R, Reichardt P, Wust P, Ghadjar P, Hohenberger P, Angele M, Salat C, Vujaskovic Z, Daugaard S, Mella O, Mansmann U, Dürr HR, Knösel T, Abdel-Rahman S, Schmidt M, Hiddemann W, Jauch KW, Belka C, Gronchi A; European Organization for the Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group and the European Society for Hyperthermic Oncology.

JAMA Oncol. 2018 Apr 1;4(4):483-492. doi: 10.1001/jamaoncol.2017.4996.

8.

Impact of adenotonsillectomy on the dentofacial development of obstructed children.

Becking B, Verweij J, van Merkesteyn R.

Eur J Orthod. 2018 Jul 27;40(4):451-452. doi: 10.1093/ejo/cjx101. No abstract available.

PMID:
29373652
9.

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.

Wajja A, Kizito D, Nassanga B, Nalwoga A, Kabagenyi J, Kimuda S, Galiwango R, Mutonyi G, Vermaak S, Satti I, Verweij J, Tukahebwa E, Cose S, Levin J, Kaleebu P, Elliott AM, McShane H.

PLoS Negl Trop Dis. 2017 May 4;11(5):e0005440. doi: 10.1371/journal.pntd.0005440. eCollection 2017 May.

10.

Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels.

Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay JY, Lindner LH, Judson IR, Schöffski P, Leyvraz S, Italiano A, Grünwald V, Pousa AL, Kotasek D, Sleijfer S, Kerst JM, Rutkowski P, Fumagalli E, Hogendoorn P, Litière S, Marreaud S, van der Graaf W, Gronchi A, Verweij J; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group.

J Clin Oncol. 2017 May 20;35(15):1713-1720. doi: 10.1200/JCO.2016.71.0228. Epub 2017 Mar 31.

PMID:
28362562
11.

Health policy: Affordability of drugs used in oncology health care.

Sleijfer S, Verweij J.

Nat Rev Clin Oncol. 2016 Jun;13(6):331-2. doi: 10.1038/nrclinonc.2016.77. Epub 2016 May 10. No abstract available.

PMID:
27161940
12.

miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway.

van Jaarsveld MT, van Kuijk PF, Boersma AW, Helleman J, van IJcken WF, Mathijssen RH, Pothof J, Berns EM, Verweij J, Wiemer EA.

Mol Cancer. 2015 Nov 17;14:196. doi: 10.1186/s12943-015-0464-4.

13.

Primary care in cancer control: towards mature cancer care.

Uyl-de Groot CA, Brouwer WB, de Maeseneer JM, Verweij J.

Lancet Oncol. 2015 Sep;16(12):1226-7. doi: 10.1016/S1470-2045(15)00294-6. No abstract available.

PMID:
26431862
14.

Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.

Duffaud F, Sleijfer S, Litière S, Ray-Coquard I, Le Cesne A, Papai Z, Judson I, Schöffski P, Chawla SP, Dewji R, Marreaud S, Verweij J, van der Graaf WT.

Eur J Cancer. 2015 Nov;51(17):2615-23. doi: 10.1016/j.ejca.2015.08.002. Epub 2015 Aug 25.

PMID:
26321011
15.

4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.

de Graan AJ, Sparreboom A, de Bruijn P, de Jonge E, van der Holt B, Wiemer EA, Verweij J, Mathijssen RH, van Schaik RH.

Br J Clin Pharmacol. 2015 Sep;80(3):560-8. doi: 10.1111/bcp.12707. Epub 2015 Aug 12.

16.

Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib.

Lee CK, Goldstein D, Gibbs E, Joensuu H, Zalcberg J, Verweij J, Casali PG, Maki RG, Cioffi A, Mcarthur G, Lord SJ, Yip D, Kanjanapan Y, Rutkowski P.

Eur J Cancer. 2015 May;51(7):852-60. doi: 10.1016/j.ejca.2015.02.015. Epub 2015 Mar 19.

PMID:
25801699
17.

Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules.

Hamberg P, Mathijssen RH, de Bruijn P, Leonowens C, van der Biessen D, Eskens FA, Sleijfer S, Verweij J, de Jonge MJ.

Cancer Chemother Pharmacol. 2015 Feb;75(2):365-71. doi: 10.1007/s00280-014-2655-x. Epub 2014 Dec 23.

PMID:
25533184
18.

Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment.

Straetemans T, Berrevoets C, Coccoris M, Treffers-Westerlaken E, Wijers R, Cole DK, Dardalhon V, Sewell AK, Taylor N, Verweij J, Debets R.

Mol Ther. 2015 Feb;23(2):396-406. doi: 10.1038/mt.2014.215. Epub 2014 Nov 3.

19.

Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials.

Le Cesne A, Ouali M, Leahy MG, Santoro A, Hoekstra HJ, Hohenberger P, Van Coevorden F, Rutkowski P, Van Hoesel R, Verweij J, Bonvalot S, Steward WP, Gronchi A, Hogendoorn PC, Litiere S, Marreaud S, Blay JY, Van Der Graaf WT.

Ann Oncol. 2014 Dec;25(12):2425-32. doi: 10.1093/annonc/mdu460. Epub 2014 Oct 6.

PMID:
25294887
20.

Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study.

Moreno García V, Olmos D, Gomez-Roca C, Cassier PA, Morales-Barrera R, Del Conte G, Gallerani E, Brunetto AT, Schöffski P, Marsoni S, Schellens JH, Penel N, Voest E, Evans J, Plummer R, Wilson RH, Soria JC, Tabernero J, Verweij J, Kaye SB.

Clin Cancer Res. 2014 Nov 15;20(22):5663-71. doi: 10.1158/1078-0432.CCR-14-0719. Epub 2014 Sep 24.

Supplemental Content

Loading ...
Support Center